TRIO Completes Enrollment for Phase II Giredestrant Early Breast Cancer Trial Ahead of Schedule

Translational Research in Oncology (TRIO) announced enrollment completion in coopERA Breast Cancer, a Phase II clinical trial of giredestrant, an oral selective estrogen receptor degrader that showed encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive metastatic breast cancer patients.